1. Academic Validation
  2. Prevention of noise-induced hearing loss with Src-PTK inhibitors

Prevention of noise-induced hearing loss with Src-PTK inhibitors

  • Hear Res. 2005 Oct;208(1-2):14-25. doi: 10.1016/j.heares.2005.04.009.
Kelly Carney Harris 1 Bohua Hu David Hangauer Donald Henderson
Affiliations

Affiliation

  • 1 Center for Hearing and Deafness, University at Buffalo, Buffalo, NY 14214, USA. harriskc@musc.edu
Abstract

Studies from our lab show that noise exposure initiates cell death by multiple pathways [Nicotera, T.M., Hu, B.H., Henderson, D., 2003. The Caspase pathway in noise-induced Apoptosis of the chinchilla cochlea. J. Assoc. Res. Otolaryngol. 4, 466-477] therefore, protection against noise may be most effective with a multifaceted approach. The Src protein tyrosine kinase (PTK) signaling cascade may be involved in both metabolic and mechanically induced initiation of Apoptosis in sensory cells of the cochlea. The current study compares three Src-PTK inhibitors, KX1-004, KX1-005 and KX1-174 as potential protective drugs for NIHL. Chinchillas were used as subjects. A 30 microl drop of one of the Src inhibitors was placed on the round window membrane of the anesthetized chinchilla; the vehicle (DMSO and buffered saline) alone was placed on the Other ear. After the drug application, the middle ear was sutured and the subjects were exposed to noise. Hearing was measured before and several times after the noise exposure and treatment using evoked responses. At 20 days post-exposure, the Animals were anesthetized their cochleae extracted and cochleograms were constructed. All three Src inhibitors provided protection from a 4 h, 4 kHz octave band noise at 106 dB. The most effective drug, KX1-004 was further evaluated by repeating the exposure with different doses, as well as, substituting an impulse noise exposure. For all conditions, the results suggest a role for Src-PTK activation in noise-induced hearing loss (NIHL), and that therapeutic intervention with a Src-PTK inhibitor may offer a novel approach in the treatment of NIHL.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-18237
    99.75%, Src Inhibitor
    Src